Kyverna Therapeutics, Inc.

The momentum for this stock is not very good. Kyverna Therapeutics, Inc. is not a good value stock. Kyverna Therapeutics, Inc. is not a good growth stock. Kyverna Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Kyverna Therapeutics, Inc..
Log in to see more information.
KYTX Fundamental Data by TradingView

News

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts

Zolmax Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat.com...\n more…

Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $34.40
Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $34.40

Ticker Report Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company...\n more…

Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation
Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

PR Newswire Kyverna Therapeutics to Participate in Upcoming September Investor Conferences Kyverna Therapeutics to Participate in Upcoming September Investor Conferences PR Newswire EMERYVILLE, Calif., Aug. 21...\n more…

HC Wainwright Comments on Kyverna Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:KYTX)
HC Wainwright Comments on Kyverna Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:KYTX)

Ticker Report Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - HC Wainwright reduced their Q3 2024 earnings per share (EPS) estimates for shares of Kyverna Therapeutics in a note issued to investors on...\n more…

Kyverna Therapeutics (NASDAQ:KYTX) PT Lowered to $7.00 at HC Wainwright
Kyverna Therapeutics (NASDAQ:KYTX) PT Lowered to $7.00 at HC Wainwright

Ticker Report Kyverna Therapeutics (NASDAQ:KYTX - Free Report) had its price objective cut by HC Wainwright from $8.00 to $7.00 in a research report released on Thursday morning, Benzinga reports. They currently...\n more…